Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis

Saved in:

Bibliographic Details
Published in:	British journal of dermatology (1951) Vol. 163; no. 6; pp. 1346 - 1347
Main Authors:	Daudén, E., Santiago-et-Sánchez-Mateos, D., Sotomayor-López, E., García-Díez, A.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-12-2010 Wiley-Blackwell
Subjects:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized biologic therapy Biological and medical sciences Biopsy Bullous diseases of the skin Dermatology Humans Immunologic Factors - therapeutic use Injections, Subcutaneous Male Medical sciences Middle Aged Psoriasis - drug therapy Psoriasis - pathology pustular psoriasis Severity of Illness Index Treatment Outcome Ustekinumab Human Skin disease Pustular psoriasis Dermatology Generalized Pustulosis dermatosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ArticleID:BJD9995 ark:/67375/WNG-KNHJS5KB-R istex:1115A7C986B21A1102C5CCD48E8A2419DC1D2475 Conflicts of interest: E.D. has been an advisory board member and consultant, received grants, research support and honoraria for speaking, or participated in clinical trials, with Abbott, Astellas, Biogen, Centocor Ortho Biotech Inc., Galderma, Glaxo, Janssen‐Cilag, Leo Pharma, Merck‐Serono, Novartis, Pfizer, Schering‐Plough, Stiefel, Wyeth Pharmaceuticals and 3M. A.G.‐D. has been an advisory board member and consultant, and received research support from Abbott and Serono. The other authors declare no conflicts of interest.
ISSN:	0007-0963 1365-2133
DOI:	10.1111/j.1365-2133.2010.09995.x